HIGHLIGHTS
SUMMARY
Targeting HHLA2-KIR3DL3 alone to inhibit the checkpoint pathway or in combination with PD1 blockade is a potential treatment (Zhou, et_al, 2020; Bhatt, et_al, 2021). The function of Treg can be inhibited by PRKCQ, while PRKCQ can activate Teff (Zanin-Zhorov, et_al, 2010). The construction of a prognostic signature has been proved to be a feasible strategy for predicting disease outcomes (Wu, et_al, 2021; Wu, et_al, 2022). Although new targeted and immune agents continue to emerge and improve the prognosis of some patients, these drugs are still not suitable for all patients (Linehan and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.